Companies ›Healthcare ›251120.KQ

251120.KQ — KOSDAQ Pharmaceuticals

251120.Kq

$9 400,00

Open in Charts → Attach watcher ⌖

— —

KRW

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

80,2B KRW

P/E

—

EV / Rev

—

Div yield

—

Op margin

32,6 %

ROE

9,6 %

Net margin

34,8 %

Debt / equity

0,01

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target19 100,00

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

19 100,00

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

1 analysts · indicative

Ownership

—

not yet wired

Profitability→

9,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 251120.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 251120.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

The company maintains a strong liquidity position, with a current ratio of 17.06, indicating a high ability to meet short-term obligations. Its cash and equivalents amount to 10,754,466,080 KRW, which is a significant portion of its total assets of 73,449,600,500 KRW. The company's price-to-book ratio is 1.4, and its price-to-tangible-book ratio is also 1.4, suggesting that the market values the company's equity at a moderate premium to its book value.

In terms of profitability, the company's return on equity (ROE) is 9.55%, and its return on assets (ROA) is 9.08%, both of which are strong indicators of efficient use of equity and assets. The company's net income of 6,666,197,110 KRW and operating income of 6,252,759,750 KRW reflect a healthy profit margin, which is in line with the typical performance of companies in the pharmaceuticals industry.

The company's revenue is primarily derived from its pharmaceutical products, with no specific segment breakdown provided in the available data. However, the company's total revenue of 19,179,051,490 KRW indicates a substantial market presence. The company's geographic exposure is not detailed, but its strong financial performance suggests a broad and stable customer base.

Looking ahead, the company is expected to maintain its growth trajectory, with a mean price target of 19,100 KRW from analysts, indicating a potential upside from the current market price of 11,440 KRW. The company's free cash flow of 7,191,866,010 KRW and operating cash flow of 7,278,678,960 KRW support its ability to fund operations and invest in future growth.

The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.01, indicating a very low level of leverage and a strong equity position. The company's capital structure is primarily equity-based, with total liabilities of 3,651,985,380 KRW and total equity of 69,797,615,120 KRW.

Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's strong financial performance and low risk profile suggest a stable and predictable business environment.

Key takeaways

The company has a strong liquidity position with a current ratio of 17.06.
The company's ROE and ROA are 9.55% and 9.08%, respectively, indicating efficient use of equity and assets.
The company's revenue of 19,179,051,490 KRW suggests a substantial market presence.
Analysts have a strong buy recommendation for the company, with a mean price target of 19,100 KRW.
The company has a low debt-to-equity ratio of 0.01, indicating a strong equity position.
The company's free cash flow and operating cash flow are robust, supporting future growth and operational needs.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$9 400,00

Market cap

$97.57B

Enterprise valueⓘ

$87.17B

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

12.0x

P / Bⓘ

1.4x

P / Tangible bookⓘ

1.4x

Tangible book

$69.80B

Net cashⓘ

$10.40B

Current ratioⓘ

17.1

Debt / equityⓘ

0.0

ROAⓘ

9.1%

ROEⓘ

9.6%

Cash conversionⓘ

109.0%

CapEx / revenueⓘ

-5.5%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy1

Buy0

Hold0

Sell0

Strong sell0

12-month price target$19 100,00 · Median $19 100,00

Low $19 100,00High $19 100,00

Operating income · consensus7,7B KRW

Revenue surprise

−10,6 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$19 100,00

Mean$19 100,00

Median$19 100,00

High$19 100,00

Spot$9 400,00

+103.2 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin32,6 %Best in class

Net Margin34,8 %Best in class

ROE9,6 %Above median

Capex / Rev-5,5 %Below median

D/E0,01Above median

Cash Conv1,09Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Ev To Operating Cash Flow
enterprise_value / operating_cash_flow
Return On Equity
net_income / total_equity
Price To Earnings
market_price / (net_income / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)

Source documents

251120.KQ Market data — financials · 2026-05-26
Bio-FD&C Co Ltd Market data — analyst estimates · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

251120.KQCanonical

KOSDAQ · KRW

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread